The global epilepsy market size was significantly robust in 2022 and is expected to register a steady revenue CAGR over the forecast period. Key factors driving market revenue growth are increasing number of road accidents, and also rapidly growing global geriatric population. Prevalence of epilepsy is higher in aged population across the globe.
Epilepsy is a central nervous system disorder where the brain activity becomes abnormal. This results in unusual behavior, loss of awareness and causes seizures. Epilepsy can be triggered during or post surgeries, and medicine treatments. Increasing incidence of brain injuries and higher rate of post-traumatic seizure occurrence in patients are factors driving revenue growth of the global epilepsy market. Increasing funding and efforts by government of various countries to enhance and develop effective drugs for the treatment of seizures and focus on research and development to provide advanced drugs are other major factors expected to boost revenue growth of the global epilepsy market.
Request a Sample@ https://www.qyresearchmedical.com/sample/119449
According to a Report published by World Health Organization (WHO), there are approximately 50 million people who are suffering from epilepsy disease globally. Various awareness campaigns are conducted by healthcare organizations worldwide to spread awareness regarding the condition and available treatment which is supporting market revenue growth.
Major Factors Driving Growth Of The Global Epilepsy Market:
Revenue growth of the global epilepsy market is significantly driven by increasing number of accidents, high incidence of brain injuries, coupled with high rate of Post Traumatic Epilepsy (PTE) and Post Traumatic Seizures (PTS) in patients with brain injuries, growing global geriatric population, resulting in high demand for epilepsy treatment.
Conditions such as cough, fever, tiredness, disruption of tissues as well as kidney, liver and nervous system may lead to epilepsy or a stroke. This is another factor expected to create need for treatment of epilepsy, thereby boosting market revenue growth to a significant extent.
Factors Restraining Growth Of The Global Epilepsy Market:
Factors such as high cost of patented medicine, time-consuming approval process, and low availability of these drugs in developing and underdeveloped countries across the globe could hamper revenue growth of the global epilepsy market to some extent.
Opportunities For Players Operating In The Global Epilepsy Market:
Various major players are focusing on research and development of advanced and novel drugs to cater to ongoing need for treatment. In addition to this, symptoms of epilepsy are being cured using certain drugs and surgeries; however there is no appropriate cure for epilepsy. Focusing on research projects to develop accurate treatment options are some of the major factors that are expected to create revenue opportunities for major players operating in the global epilepsy market.
Global Epilepsy Market Revenue Led By Diagnosis and Treatment Segment:
Based on diagnosis and treatment, the global epilepsy market is segmented into diagnosis and treatment. The diagnosis segment accounted for the largest revenue share in the global epilepsy market in 2020, and is expected to register a robust revenue growth rate during the forecast period. This is due to rising need for diagnosis before making decisions about treatment to be given. Diagnosis is a very important step in analyzing the symptoms to reach to conclusion.
The treatment segment is expected to register the highest revenue growth rate over the forecast period, owing to increasing incidence of epilepsy in patients with brain injuries, and rising prevalence of the condition in rapidly growing geriatric population globally. In addition, constant focus of players on advancements in the medication for epilepsy is driving revenue growth of this segment.
Global Epilepsy Market Leading End-Use Segment:
Based on the end-use, the global epilepsy market has been segmented into hospitals, diagnostic centers, clinics, and ambulatory surgical centers. The hospital segment accounted for major revenue share in the global epilepsy market in 2020, because government is providing funding for treatment facilities in hospitals across various regions, and increasing patient footfall in hospitals.
North America Accounts For Largest Revenue Share In Global Epilepsy Market:
North America accounted for the largest revenue share in 2020, due to increasing government initiatives for spreading awareness regarding the condition and treatments available, as well as favorable reimbursement scenarios. In addition, well-developed healthcare infrastructure, presence of major players in the region, and rising research and development activities by players are other major factors supporting market revenue growth in North America.
Asia Pacific Continues To Lead In Terms Of Revenue CAGR:
The Asia Pacific epilepsy market is expected to register the fastest growth in CAGR over forecast period of 2021–2032. The support from government plays important role. To improve the treatment facilities in the emerging economies, funding is being provided from the government. In addition, rising awareness among patients and increasing spending on health & wellness, and advanced treatment for epilepsy is driving market growth in in the region.
Major Companies Profiled In The Report:
- LivaNova PLC
- Pfizer Inc.
- GlaxoSmithKline PLC
- Eisai Co. Ltd.
- Medtronic PLC
- Abbott Laboratories
- Johnson & Johnson Services Inc.
- Novartis AG
- UCB SA
Strategies And Objectives Of Major Companies:
- LivaNova PLC is continuously working on the advancement of their VNS (Vagus Nerve Stimulation) therapy system. It is FDA Approved treatment for DRE (Drug Resistant Epilepsy). Along with this, it is conducting Epilepsy Awareness Month in partnership.
- Pfizer Inc. has been assessing the use of LYRICA, which is adjunctive therapy for epilepsy patients with age range of 5-65 years. The company has initiated the phase 3 of study in LYRICA.
- Eisai Co. Ltd has discovered and developed Perampanel, first-in-class anti-epileptic agent (AED). This agent is highly selective and reduces neuronal hyper excitation of seizures. It is approved in more than 70 countries.
What Our Report Provides And Why Our Offering Is Better:
This report offers historical data points and forecasts and revenue growth at a global, regional, and country level, and provides analysis, industry trends, and consumption pattern details for each region, major country, and segment from 2023 to 2032. The global market report includes industry trends, drivers, restraints, opportunities, threats, market strategies, segment revenue, and market share contribution by each regional and country market. In addition, the report offers industry analysis and competitive landscape, company financials, and impact analysis. The report includes a detailed view of the global market, along with changing dynamics and trends, scenarios, detailed market and regional segmentation, regional landscape, analysis and evaluation, major investments, product offerings, product launches, and details of historical, current, and projected revenues.
Detailed Segmentation In Our Report:
For the purpose of this report, the global epilepsy market is segmented on the basis of condition, diagnosis and treatment, end use, region:
Condition Outlook (Revenue, USD Billion; 2023-2032)
- DRE (Drug Resistant Epilepsy)
Diagnosis and Treatment Outlook (Revenue, USD Billion; 2023-2032)
- Blood Tests
- Imaging Devices
- Neurostimulation Devices
- Anti-Epileptic Drugs
- Ketogenic Diet
- Brain Surgery
End-Use Outlook (Revenue, USD Billion; 2023-2032)
- Diagnostic Centers
- Ambulatory Surgical Centers
Region Outlook (Revenue, USD Billion; 2023-2032)
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- Latin America
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Buy quantitative research Report at discounted price – USD 1500 https://www.qyresearchmedical.com/report/checkout/119449/1500
You can place an order or ask any questions, please feel free to contact firstname.lastname@example.org | +1 9197 992 333
QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover North America, Europe, Latin America, Middle East and Africa, Asia- Pacific.
For Latest Update Follow Us: